Vascular disruptive agent OXi4503 and anti-angiogenic agent Sunitinib combination treatment prolong survival of mice with CRC liver metastasis.
about
Salinomycin exhibits anti-angiogenic activity against human glioma in vitro and in vivo by suppressing the VEGF-VEGFR2-AKT/FAK signaling axis.E-cadherin: A potential biomarker of colorectal cancer prognosis.The role of tumor microenvironment in resistance to anti-angiogenic therapy.Spatiotemporal heterogeneity of tumor vasculature during tumor growth and antiangiogenic treatment: MRI assessment using permeability and blood volume parameters.
P2860
Vascular disruptive agent OXi4503 and anti-angiogenic agent Sunitinib combination treatment prolong survival of mice with CRC liver metastasis.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Vascular disruptive agent OXi4 ...... ice with CRC liver metastasis.
@ast
Vascular disruptive agent OXi4 ...... ice with CRC liver metastasis.
@en
type
label
Vascular disruptive agent OXi4 ...... ice with CRC liver metastasis.
@ast
Vascular disruptive agent OXi4 ...... ice with CRC liver metastasis.
@en
prefLabel
Vascular disruptive agent OXi4 ...... ice with CRC liver metastasis.
@ast
Vascular disruptive agent OXi4 ...... ice with CRC liver metastasis.
@en
P2860
P1433
P1476
Vascular disruptive agent OXi4 ...... mice with CRC liver metastasis
@en
P2093
Linh Nguyen
Theodora Fifis
P2860
P2888
P356
10.1186/S12885-016-2568-7
P407
P577
2016-07-26T00:00:00Z
P6179
1003289993